回顾性评估肺癌患者当日使用培非格司亭的安全性和有效性。
Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer.
机构信息
Department of Pharmacy Practice & Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.
Department of Health Sciences, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
出版信息
Future Oncol. 2022 Jun;18(19):2381-2390. doi: 10.2217/fon-2022-0166. Epub 2022 Apr 28.
To determine the incidence of chemotherapy-induced febrile neutropenia (FN) and related outcomes after same-day pegfilgrastim in lung cancer. This single-center, retrospective study evaluated electronic health records of patients with lung cancer treated between 2013-2018. The main end points were incidence of FN and grade 3/4 neutropenia after the first and across all chemotherapy cycles. A total of 114 patients received same-day pegfilgrastim in 384 cycles. The incidence of FN and grade 3/4 neutropenia was 2.3 and 25% after the first chemotherapy cycle and 1.6 and 10.4% across all cycles, respectively. Same-day prophylactic pegfilgrastim in patients with lung cancer may be a suitable option, owing to its low incidence of FN and related outcomes.
目的
确定肺癌患者在同一天接受培非格司亭后的发热性中性粒细胞减少（FN）发生率及其相关结局。
方法
本单中心回顾性研究评估了 2013-2018 年间接受治疗的肺癌患者的电子健康记录。主要终点为首次化疗后和所有化疗周期中 FN 的发生率和 3/4 级中性粒细胞减少症。共有 114 例患者在 384 个周期中接受了同日培非格司亭治疗。首次化疗周期后 FN 和 3/4 级中性粒细胞减少症的发生率分别为 2.3%和 25%，所有周期的发生率分别为 1.6%和 10.4%。
结论
由于肺癌患者 FN 发生率及其相关结局较低，同日预防性培非格司亭可能是一种合适的选择。
Zotero 插件